摘要
目的探讨西妥昔单抗与胰岛素样生长因子-Ⅰ受体（IGF-ⅠR）抑制剂aIR3对人肝癌细胞株HepG2细胞的作用。方法选用浓度递增的西妥昔单抗（5-500）mg／mL和aIR3（2．5～250．0）μmol／L，单独或联合作用于HepG2细胞，观察不同时间对细胞增殖的抑制作用以及联用时的两药协同系数。结果单药西妥昔单抗与aIR3对HepG2细胞增殖的抑制作用均呈浓度依赖性与时间依赖性，二药单独作用于HepG2细胞72h最大抑制率分别为42．2％、82．3％，二药联合作用于HepG2细胞72h最大抑制率达91．8％。西妥昔单抗与aIR3不同浓度在各时间点的协同系数均小于1。结论西妥昔单抗和aIR3在体外对HepG2细胞的增殖均具有一定的抑制作用，联合应用时具有明显的协同效应。
Objective To evaluate the effects of cetuximab combined with inhibitor of insulin-like growth factor- Ⅰ receptor （IGF- ⅠR） aIR3 on proliferation of human hepatocellular carcinoma cell （HCC） lines HepG2. Methods Increasing concen- trations of cetuximab （5-500） mg/mL and aIR3 （2.5-250.0） μmol/L, alone or in combination were administrated to HepG2 ceils. The inhibitory effects of the drugs on cell proliferation at different time points were observed;the combination index （CI） of these two agents was calculated. Results The single agent of cetuximab and aIR3 inhibited the proliferation of HCC cells in a time- and dose-dependent manner. After treatment 72-hour,the proliferation inhibition rates of HepG2 cells were 42.2% and 82.3%. With maximal inhibitory effects of cetuximab combined aIR3, the proliferation inhibition rates of HepG2 was 91.8%. The CIs of different concentrations of the two agents at different time points were all less than 1, suggested that they have obvious synergistic activity. Conclusion The single agent of cetuximab and aIR3 can inhibit the proliferation of HepG2 cells, and they have obvious synergistic activity.
出处
《中国现代医生》
2012年第26期1-3,共3页
China Modern Doctor
基金
浙江省湖州市科技项目(2009YS06)
